A Chinese firm, a U.S. startup on the brink, and lobbyists with political ties—Washington’s influence game is back in the spotlight.
A little-known lobbying effort has delivered a rare victory for a Chinese company in Washington—raising new questions about influence, access, and national security oversight.
At the center of the case is China’s Grand Pharmaceutical Group, which successfully fended off a U.S. startup’s attempt to trigger a national security review of its investment. The decision by the Committee on Foreign Investment in the United States effectively allowed the Chinese firm to maintain its stake—despite concerns raised by the American company.
The turning point came after Grand Pharma hired a lobbying firm with personal ties to Donald Trump Jr.. The firm helped arrange a high-level meeting with senior U.S. officials, giving the Chinese company direct access to decision-makers at a critical moment.
Soon after, the watchdog rejected the filing brought by Minnesota-based FastWave—not on national security grounds, but over what it described as “material misstatements” in the company’s submission. The ruling avoided addressing whether the Chinese investment posed any strategic risk.
For FastWave, the consequences have been severe. The company, which develops laser-based medical technology with potential dual-use applications, now faces financial collapse. Its leadership had argued that the Chinese investor’s involvement risked intellectual property exposure and could hinder future funding.
Grand Pharma disputes those claims, framing the case as a commercial disagreement rather than a security threat.
The broader concern, however, goes beyond a single dispute.
Experts and lawmakers warn the episode highlights a structural vulnerability: that foreign companies can navigate U.S. political systems by leveraging connections within the governing orbit. While such lobbying is legal and common, critics argue the stakes are higher when national security questions intersect with foreign investment.
The White House has rejected those concerns, insisting that CFIUS processes remain rigorous and independent.
Still, the optics are difficult to ignore. A Chinese firm gained access, made its case at the highest level, and secured a favorable outcome—while its U.S. counterpart struggled to reach the same decision-makers.
Whether coincidence or influence, the episode underscores a shifting reality in Washington: access matters.
And in a system where policy, politics, and security overlap, who gets heard—and when—can shape outcomes as much as the facts themselves.
